Efficacy of stem cell mobilization in patients with newly diagnosed multiple myeloma after a CTD (cyclophosphamide, thalidomide, and dexamethasone) regimen

International Journal of Hematology

Volumn 97, Issue 1, 2013, Pages 92-97

  Jung, Sung Hoon ^a   Park, Hyungchul ^a   Ahn, Jae Sook ^a   Yang, Deok Hwan ^a   Kim, Mi Young ^a   Kim, Yeo Kyeoung ^a   Kim, Hyeoung Joon ^a   Lee, Je Jung ^a  

^a Chonnam National University   (South Korea)

Author keywords

Cyclophosphamide; Dexamethasone; Multiple myeloma; Stem cell mobilization; Thalidomide

Indexed keywords

CYCLOPHOSPHAMIDE; DEXAMETHASONE; THALIDOMIDE;

ADULT; AGED; APHERESIS; ARTICLE; CLINICAL ARTICLE; DEEP VEIN THROMBOSIS; FEBRILE NEUTROPENIA; FEMALE; GASTROINTESTINAL STROMAL TUMOR; HUMAN; MALE; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; PATIENT COMPLIANCE; STEM CELL MOBILIZATION; THERAPY EFFECT; TREATMENT DURATION; TREATMENT RESPONSE;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; DEXAMETHASONE; FEMALE; HEMATOPOIETIC STEM CELL MOBILIZATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; NEOPLASM STAGING; REMISSION INDUCTION; THALIDOMIDE; TISSUE AND ORGAN HARVESTING;

EID: 84872935549     PISSN: 09255710     EISSN: 18653774     Source Type: Journal    
DOI: 10.1007/s12185-012-1237-0     Document Type: Article

References (27)

1. Kristinsson SY, Landgren O, Dickman PW, Derolf AR, Bjorkholm M. Patterns of survival in multiple myeloma: A population-based study of patients diagnosed in Sweden from 1973 to 2003. J Clin Oncol. 2007;25:1993-9. (Pubitemid 46972782)
2. Brenner H, Gondos A, Pulte D. Recent major improvement in long-term survival of younger patients with multiple myeloma. Blood. 2008;111:2521-6.
3. Kumar SK, Rajkumar SV, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood. 2008;111:2516-20.
4. Palumbo A, Anderson K. Multiple myeloma. N Engl J Med. 2011;364:1046-60.
5. Kumar S, Giralt S, Stadtmauer EA, Harousseau JL, Palumbo A, Bensinger W, et al. Mobilization in myeloma revisited: IMWG consensus perspectives on stem cell collection following initial therapy with thalidomide-, lenalidomide-, or bortezomib-containing regimens. Blood. 2009;114:1729-35.
6. Kim JE, Yoo C, Kim S, Lee DH, Kim SW, Lee JS, et al. Optimal timing of G-CSF administration for effective autologous stem cell collection. Bone Marrow Transplant. 2011;46:806-12.
7. Cavallo F, Bringhen S, Milone G, Ben-Yehuda D, Nagler A, Calabrese E, et al. Stem cell mobilization in patients with newly diagnosed multiple myeloma after lenalidomide induction therapy. Leukemia. 2011;25:1627-31.
8. Kumar S, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, Gastineau DA, et al. Impact of lenalidomide therapy on stem cell mobilization and engraftment post-peripheral blood stem cell transplantation in patients with newly diagnosed myeloma. Leukemia. 2007;21:2035-42. (Pubitemid 47299979)
9. Popat U, Saliba R, Thandi R, Hosing C, Qazilbash M, Anderlini P, et al. Impairment of filgrastim-induced stem cell mobilization after prior lenalidomide in patients with multiple myeloma. Biol Blood Marrow Transplant. 2009;15:718-23.
10. Koh KR, Janz M, Mapara MY, Lemke B, Stirling D, Dorken B, et al. Immunomodulatory derivative of thalidomide (IMiD CC-4047) induces a shift in lineage commitment by suppressing erythropoiesis and promoting myelopoiesis. Blood. 2005;105:3833-40. (Pubitemid 40656125)
11. Rajkumar SV, Blood E, Vesole D, Fonseca R, Greipp PR. Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: A clinical trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol. 2006;24:431-6. (Pubitemid 46630462)
12. Cavo M, Zamagni E, Tosi P, Tacchetti P, Cellini C, Cangini D, et al. Superiority of thalidomide and dexamethasone over vincristine-doxorubicin- dexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma. Blood. 2005;106:35-9. (Pubitemid 40967171)
13. Sidra G, Williams CD, Russell NH, Zaman S, Myers B, Byrne JL. Combination chemotherapy with cyclophosphamide, thalidomide and dexamethasone for patients with refractory, newly diagnosed or relapsed myeloma. Haematologica. 2006;91:862-3. (Pubitemid 44014564)
14. Yang DH, Kim YK, Sohn SK, Chung JS, Joo YD, Lee JH, et al. Induction treatment with cyclophosphamide, thalidomide, and dexamethasone in newly diagnosed multiple myeloma: A phase II study. Clin Lymphoma Myeloma Leuk. 2010;10:62-7.
15. Morgan GJ, Davies FE, Gregory WM, Russell NH, Bell SE, Szubert AJ, et al. Cyclophosphamide, thalidomide, and dexamethasone (CTD) as initial therapy for patients with multiple myeloma unsuitable for autologous transplantation. Blood. 2011;118:1231-8.
16. Morgan GJ, Davies FE, Gregory WM, Bell SE, Szubert AJ, Navarro Coy N, et al. Cyclophosphamide, thalidomide, and dexamethasone as induction therapy for newly diagnosed multiple myeloma patients destined for autologous stem-cell transplantation: MRC Myeloma IX randomized trial results. Haematologica. 2012;97(3):442-50.
17. Raab MS, Podar K, Breitkreutz I, Richardson PG, Anderson KC. Multiple myeloma. Lancet. 2009;374:324-39.
18. Attal M, Harousseau JL, Stoppa AM, Sotto JJ, Fuzibet JG, Rossi JF, et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N Eng J Med. 1996;335:91-7. (Pubitemid 26240110)
19. Cavo M, Tosi P, Zamagni E, Cellini C, Tacchetti P, Patriarca F, et al. Prospective, randomized study of single compared with double autologous stem-cell transplantation for multiple myeloma: Bologna 96 clinical study. J Clin Oncol. 2007;25:2434-41. (Pubitemid 46999214)
20. Breitkreutz I, Lokhorst HM, Raab MS, Holt B, Cremer FW, Herrmann D, et al. Thalidomide in newly diagnosed multiple myeloma: influence of thalidomide treatment on peripheral blood stem cell collection yield. Leukemia. 2007;21:1294-9. (Pubitemid 46831819)
21. Auner HW, Mazzarella L, Cook L, Szydlo R, Saltarelli F, Pavlu J, et al. High rate of stem cell mobilization failure after thalidomide and oral cyclophosphamide induction therapy for multiple myeloma. Bone Marrow Transplant. 2011;46:364-7.
22. Lefrere F, Zohar S, Ghez D, Delarue R, Audat F, Suarez F, et al. The VAD chemotherapy regimen plus a G-CSF dose of 10 μg/kg is as effective and less toxic than high-dose cyclophosphamide plus a G-CSF dose of 5 μg/kg for progenitor cell mobilization: results from a monocentric study of 82 patients. Bone Marrow Transplant. 2006;37:725-9.
23. Morris CL, Siegel E, Barlogie B, Cottler-Fox M, Lin P, Fassas A, et al. Mobilization of CD34+ cells in elderly patients (≥70 years) with multiple myeloma: influence of age, prior therapy, platelet count and mobilization regimen. Br J Haematol. 2003;120:413-23. (Pubitemid 36241497)
24. Lutsiak ME, Semnani RT, De Pascalis R, Kashmiri SV, Schlom J, Sabzevari H. Inhibition of CD4(+)25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide. Blood. 2005;105:2862-8. (Pubitemid 40446280)
25. Sharabi A, Haran-Ghera N. Immune recovery after cyclophosphamide treatment in multiple myeloma: implication for maintenance immunotherapy. Bone Marrow Res. 2011;2011:269519.
26. Ghiringhelli F, Menard C, Puig PE, Ladoire S, Roux S, Martin F, et al. Metronomic cyclophosphamide regimen selectively depletes CD4+ CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients. Cancer Immunol Immunother. 2007;56:641-8. (Pubitemid 46348738)
27. Gertz MA, Kumar SK, Lacy MQ, Dispenzieri A, Hayman SR, Buadi FK, et al. Comparison of high-dose CY and growth factor with growth factor alone for mobilization of stem cells for transplantation in patients with multiple myeloma. Bone Marrow Transplant. 2009;43:619-25.